研究单位：[1]Nanfang Hospital, Southern Medical University[2]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230022[3]Beijing Chaoyang Hospital, Capital Medical University,Beijing,Beijing,China,100016[4]Xinqiao Hospital of Chongqing,Chongqing,Chongqing,China,400037[5]Southern Medical University Zhujiang Hospital,Guangzhou,Guangdong,China,510260[6]Southern Medical University Nanfang Hospital,Guangzhou,Guangdong,China,510515[7]The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China,550001[8]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[9]Henan Provincial People's Hospital,Zhengzhou,Henan,China,450003[10]Wuhan University People's Hospital,Wuhan,Hubei,China,430060[11]Hunan Provincial People's Hospital,Changsha,Hunan,China,410002[12]Jiangsu Provincial People's Hospital,Nanjing,Jiangsu,China,210029[13]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330008[14]General Hospital of Northern Theater Command,Shenyang,Liaoning,China,110016[15]The First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China,030001[16]Sichuan Provincial People's Hospital,Chengdu,Sichuan,China,610072[17]The First People's Hospital of Yunnan Province,Kunming,Yunnan,China,650028[18]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032
研究目的：
The goal of this randomized controlled trial is to compare total intravenous anesthesia with remimazolam vs total intravenous anesthesia with propofol in moderate-to-high risk patients undergoing major elective noncardiac surgery under general anesthesia. The primary hypothesis is that total intravenous anesthesia with remimazolam can increase days alive and out of hospital at postoperative day 30 compared with total intravenous anesthesia with propofol.
